CTRI/2019/02/017692尚未招募未知
An open-label, comparative (6-weeks vs 2-weeks treatment) study on safety and efficacy of Moxifloxacin (0.5%) plus Dexamethasone (0.1%) Ophthalmic solution in post-cataract cases.
Santhiram Medical College and General Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1) Male & Female patients aged above 18 years.
- •2) Diagnosed with cataract and undergo surgery for the same.
- •3) Initiated treatment with any one of the 3 patterns - Moxifloxacin (0.5%) + Dexamethasone (0.1%) for 6 weeks (OR) Moxifloxacin (0.5%) + Dexamethasone (0.1%) for 2 weeks (OR) Moxifloxacin (0.5%) + Prednisolone (1%) for 6 weeks.
- •4) Willing to give voluntary written informed consent.
排除标准
- •1) Aged below 18 years.
- •2) Not willing to participate.
- •3) Uncontrolled Glaucoma.
- •4) Intraocular hypertension.
- •5) Chronic or recurrent ocular inflammatory disease (i.e., iritis, scleritis, uveitis).
- •6) Intraocular inflammation or Ocular pain in the study eye prior to the surgery.
- •7) Traumatic cataract.
- •8) Complicated cataract.
- •9) Intraocular complications.
- •10) Patients with only one eye.
研究者
相似试验
招募中
4 期
A clinical trial to study the effects of two drugs, viladozone and fluoxetine in major depressive patients for 6 weeksCTRI/2017/03/008202Mysore medical college and research institute72
进行中（未招募）
不适用
A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE) - PALATPrimary Nocturnal EnuresisMedDRA version: 6.1Level: LLTClassification code 10029453EUCTR2004-000593-32-SEFerring Pharmaceuticals A/S200
进行中（未招募）
1 期
A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)Primary Nocturnal EnuresisMedDRA version: 6.1 Level: low Classification code 10029453EUCTR2004-000593-32-GBFerring Pharmaceuticals A/S200
进行中（未招募）
不适用
A 6-week open label cross-over study with 2 different daily doses of Minirin oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)Primary Nocturnal EnuresisMedDRA version: 6.1Level: lowClassification code 10029453EUCTR2004-000593-32-DEFerring Arzneimittel GmbH200
进行中（未招募）
不适用
A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE) - PALATPrimary Nocturnal EnuresisMedDRA version: 6.1Level: LLTClassification code 10029453EUCTR2004-000593-32-FIFerring Pharmaceuticals A/S200